Investments in cancer research awarded to UK institutions and the global burden of cancer 2000–2013: a systematic analysis
Open Access
Abstract
Objectives To systematically categorise cancer research investment awarded to United Kingdom (UK) institutions in the period 2000–2013 and to estimate research investment relative to disease burden as measured by mortality, disability-adjusted life years (DALYs) and years lived with disability (YLDs). Design Systematic analysis of all open-access data. Setting and participants Public and philanthropic funding to all UK cancer research institutions, 2000–2013. Main outcome measures Number and financial value of cancer research investments reported in 2013 UK pounds (UK£). Mortality, DALYs and YLDs data were acquired from the Global Burden of Disease Study. A compound metric was adapted to estimate research investment relative to disease burden as measured by mortality, DALYs and YLDs. Results We identified 4299 funded studies with a total research investment of £2.4 billion. The highest fundings by anatomical sites were haematological, breast, prostate, colorectal and ovarian cancers. Relative to disease burden as determined by a compound metric combining mortality, DALYs and YLDs, gender-specific cancers were found to be highest funded—the five sites that received the most funding were prostate, ovarian, breast, mesothelioma and testicular cancer; the least well-funded sites were liver, thyroid, lung, upper gastrointestinal (GI) and bladder. Preclinical science accounted for 66.2% of award numbers and 62.2% of all funding. The top five areas of primary research focus by funding were pathogenesis, drug therapy, diagnostic, screening and monitoring, women's health and immunology. The largest individual funder was the Medical Research Council. In combination, the five lowest funded site-specific cancers relative to disease burden account for 47.9%, 44.3% and 20.4% of worldwide cancer mortality, DALYs and YLDs. Conclusions Research funding for cancer is not allocated according to relative disease burden. These findings are in line with earlier published studies. Funding agencies and industry should openly document their research investments to improve better targeting of research investment.Keywords
This publication has 27 references indexed in Scilit:
- Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012Radiotherapy and Oncology, 2014
- Economic burden of cancer across the European Union: a population-based cost analysisThe Lancet Oncology, 2013
- UK investments in global infectious disease research 1997–2010: a case studyThe Lancet Infectious Diseases, 2013
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- A comparison of cancer burden and research spending reveals discrepancies in the distribution of research fundingBMC Public Health, 2012
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future ResearchCancer Epidemiology, Biomarkers & Prevention, 2011
- Relación en España entre la investigación sanitaria financiada por el Sistema Nacional de Salud y la carga de enfermedad en la comunidadRevista Espanola de Salud Publica, 2009
- Role of radiotherapy in cancer control in low-income and middle-income countriesThe Lancet Oncology, 2006
- The Relation between Funding by the National Institutes of Health and the Burden of DiseaseNew England Journal of Medicine, 1999